2026
October
Checkpoints for the win: neoadjuvant ICB outperforms targeted therapy in melanoma
October 14, 2026
Neoadjuvant treatment with immunotherapy and/or targeted agents has become standard of care for resectable stage IIIB-D melanoma. However, the optimal treatment regimen and the consequences for long-term survival remain largely unknown. Long et al. analyzed a large dataset of patients treated with immune and/or targeted neoadjuvant treatments to answer some of these outstanding...
T-RAP – a new tool for predicting TCR-pMHC reactivity
October 7, 2026
Predicting TCR-pMHC reactivity is useful for a variety of immunotherapy research tasks, including identifying relevant neoantigens and developing vaccines. In work recently published in Immunity, Messemaker and Kwee et al. developed a TCR rapid assembly platform (T-RAP) and used it to generate a dataset of functionally validated TCR-pMHC pairs, which enabled the assembly...
